For Immediate Release
Date: Sept 3, 2014
Contact: Michelle McAdam (310) 902-1274
SinuSys Corp. Names Robert Hoxie as Chief Commercial Officer
Kyabé PALO ALTO, Calif. – Sep 3, 2014 – SinuSys™ Corp., an innovative sinus health company, today announced that Robert Hoxie has joined the company as chief commercial officer, effective September 1. Mr. Hoxie will provide strategic sales and marketing direction for SinuSys and will be responsible for maintaining, developing and leading the Company’s commercial operations.
“Robert has the perfect balance of medical device sales and marketing expertise, leadership experience in the ENT market, and a proven track record of commercial success,” said Thomas Schreck, president and chief executive officer of SinuSys. “We are excited to welcome him to the SinuSys executive team and look forward to his leadership in building a first class commercial organization to support the Vent-Os™ Sinus Dilation System, our unique osmotic dilation treatment for patients suffering from recurrent sinusitis.”
Mr. Hoxie has over 30 years of experience in medical device sales and marketing management. Most recently, he served as president and CEO of Gyrus ACMI’s ENT division. There, he transformed a minimal growth company, heavily dependent on contract sales representatives, into a profitable organization within two years using direct sales, growing revenues to more than $50 million annually. As a member of the senior management team of several emerging companies, including Ovamed Corporation, Paramed Technologies, InnerDyne Corporation and Medical Innovations Corporation, he helped complete profitable acquisitions by major companies.
About SinuSys Corp.
SinuSys Corp. (www.sinusys.com) is an innovative sinus health company focused on the development and commercialization of the Vent-Os™ Sinus Dilation System and other osmotic and rate-controlled therapies for the treatment of sinusitis and other ear, nose and throat conditions. The company’s proprietary self-expanding, osmotic technology is designed to be atraumatic, tissue-sparing and easy to use, potentially enabling clinicians to intervene at earlier stages of sinus disease. The company seeks to provide improved options for the 20 percent of sinusitis patients whose disease is not resolved with drug therapy.